This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

W. Ted Brown, MD, PhD; George E. Houck, Jr, MS; Anna Jeziorowska, PhD; Faye N. Levinson, MS; Xiaohua Ding; Carl Dobkin, PhD; Nan Zhong, MD; Jeanine Henderson; Susan Sklower Brooks, MD; Edmund C. Jenkins, PhD

JAMA. 1993;270(13):1569-1575.

Abstract
Objective.
—To develop a rapid, nonradioactive test using the polymerase chain reaction (PCR) capable of detecting full fragile X mutations, premutations, and resolving normal alleles and to apply this to prenatal diagnosis and carrier screening of pregnant women at risk for fragile X carrier status.

Design.
—Prenatal and blood sample PCR analysis with confirmation by direct Southern blotting and cytogenetic techniques.

Setting.
—Samples sent to a DNA diagnostic research laboratory at a tertiary referral center.

Participants.
—Pregnant women with a family history of undiagnosed mental retardation or known fragile X syndrome and controls.

Results.
—A rapid, nonradioactive PCR screening protocol for the fragile X mental retardation-1 gene for both normal and mutant alleles was developed. Analysis of 570 control X chromosomes showed a modal number of 30 CGG repeats (range, 12 to 52 repeats) and a calculated heterozygosity of approximately 80%. No excess of homozygosity was found, indicating the test was accurate for normal allele resolution. In addition, 150 unrelated pregnant women were screened. Within known fragile X families, five of 20 pregnant women were diagnosed as carriers. Two new fragile X families were diagnosed among relatives of 130 females with family histories of undiagnosed mental retardation, although no carriers were identified. Prenatal PCR testing of 28 carriers accurately detected nine fetuses with full mutations.

Conclusions.
—This rapid, nonradioactive PCR protocol allows accurate resolution of normal alleles as well as simultaneous detection of carrier alleles and full mutations. With this approach, efficient screening of pregnant women at risk for fragile X carrier status, subsequent genetic counseling of identified carriers, and reliable prenatal diagnosis can be offered.

(JAMA. 1993;270:1569-1575)

Author Affiliations
From the New York State Institute for Basic Research in Developmental Disabilities, Staten Island. Dr Jeziorowska is now with the Medical University of Lodz (Poland).

Footnotes
Presented, in part, at the annual meeting of the American Society of Human Genetics, November 12, 1992, San Francisco, Calif.

Reprint requests to the Department of Human Genetics, Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Rd, Staten Island, NY 10314 (Dr Brown).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Expansion of an FMR1 Grey-Zone Allele to a Full Mutation in Two Generations
Fernandez-Carvajal et al.
J. Mol. Diagn. 2009;11:306-310.
ABSTRACT | FULL TEXT  

The quadruplex r(CGG)n destabilizing cationic porphyrin TMPyP4 cooperates with hnRNPs to increase the translation efficiency of fragile X premutation mRNA
Ofer et al.
Nucleic Acids Res 2009;37:2712-2722.
ABSTRACT | FULL TEXT  

Prevalence of the Fragile X Syndrome Among Estonian Mentally Retarded and the Entire Children's Population
Puusepp et al.
J Child Neurol 2008;23:1400-1405.
ABSTRACT  

Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study
Rohr et al.
Hum Reprod 2008;23:1220-1225.
ABSTRACT | FULL TEXT  

Detection of early FXTAS motor symptoms using the CATSYS computerised neuromotor test battery
Allen et al.
J. Med. Genet. 2008;45:290-297.
ABSTRACT | FULL TEXT  

The tetraplex (CGG)n destabilizing proteins hnRNP A2 and CBF-A enhance the in vivo translation of fragile X premutation mRNA
Khateb et al.
Nucleic Acids Res 2007;35:5775-5788.
ABSTRACT | FULL TEXT  

Examination of reproductive aging milestones among women who carry the FMR1 premutation
Allen et al.
Hum Reprod 2007;22:2142-2152.
ABSTRACT | FULL TEXT  

Size bias of fragile X premutation alleles in late-onset movement disorders
Jacquemont et al.
J. Med. Genet. 2006;43:804-809.
ABSTRACT | FULL TEXT  

The effect of pre-mutation of X chromosome CGG trinucleotide repeats on brain anatomy
Moore et al.
Brain 2004;127:2672-2681.
ABSTRACT | FULL TEXT  

The (CGG)n repeat element within the 5' untranslated region of the FMR1 message provides both positive and negative cis effects on in vivo translation of a downstream reporter
Chen et al.
Hum Mol Genet 2003;12:3067-3074.
ABSTRACT | FULL TEXT  

Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers
Greco et al.
Brain 2002;125:1760-1771.
ABSTRACT | FULL TEXT  

A majority of fragile X males with methylated, full mutation alleles have significant levels of FMR1 messenger RNA
Tassone et al.
J. Med. Genet. 2001;38:453-456.
ABSTRACT | FULL TEXT  

Factors involved in the initial mutation of the fragile X CGG repeat as determined by sperm small pool PCR
Crawford et al.
Hum Mol Genet 2000;9:2909-2918.
ABSTRACT | FULL TEXT  

Fragile X CGG repeat structures among African-Americans: identification of a novel factor responsible for repeat instability
Crawford et al.
Hum Mol Genet 2000;9:1759-1769.
ABSTRACT | FULL TEXT  

FRAXA and FRAXE: the results of a five year survey
Youings et al.
J. Med. Genet. 2000;37:415-421.
ABSTRACT | FULL TEXT  

Fragile X Mental Retardation Protein: Nucleocytoplasmic Shuttling and Association with Somatodendritic Ribosomes
Feng et al.
J. Neurosci. 1997;17:1539-1547.
ABSTRACT | FULL TEXT  

Molecular Predictors of Cognitive Involvement in Female Carriers of Fragile X Syndrome
Taylor et al.
JAMA 1994;271:507-514.
ABSTRACT  

Advances in Molecular Analysis of Fragile X Syndrome
Warren and Nelson
JAMA 1994;271:536-542.
ABSTRACT